Euroopa Liit - eesti - EMA (European Medicines Agency)

zoetis belgium sa - oklatsitiniibmaleaat - dermatiidi ained, välja arvatud kortikosteroidid - koerad - - treatment of pruritus associated with allergic dermatitis in dogs. - treatment of clinical manifestations of atopic dermatitis in dogs.

Eesti - eesti - Ravimiamet

uab bayer - loratadiin - tablett - 10mg 100tk; 10mg 30tk; 10mg 10tk

Eesti - eesti - Ravimiamet

ideal trade links uab - loratadiin - tablett - 10mg 10tk

Eesti - eesti - Ravimiamet

lex ano uab - loratadiin - tablett - 10mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 ja 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer limited - tofacitinib - artriit, reumatoidartriit - immunosupressandid - reumatoidartriidi ravis.

Eesti - eesti - Ravimiamet

janssen-cilag s.p.a. - erdafitiniib - õhukese polümeerikattega tablett - 3mg 30tk

Eesti - eesti - Ravimiamet

janssen-cilag s.p.a. - erdafitiniib - õhukese polümeerikattega tablett - 5mg 30tk

Eesti - eesti - Ravimiamet

janssen-cilag s.p.a. - erdafitiniib - õhukese polümeerikattega tablett - 4mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

ab science s.a. - masitinib mesilate - antineoplastilised ained - koerad - ravi mitte-resectable koer mast-rakkude kasvajad (klass 2 või 3), kellel on kinnitatud muteerunud c-kit türosiin-kinase retseptori.